Cocrystal Pharma, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
19805 N. CREEK PARKWAY, BOTHELL, WA, 98011
Mailing Address
19805 N. CREEK PARKWAY, BOTHELL, WA, 98011
Phone
(786) 459-1831
Fiscal Year End
1231
EIN
352528215
Financial Overview
FY2025
$-0.78
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | April 2, 2026 | View on SEC |
| 10-K Annual financial report | March 31, 2026 | View on SEC |
| 8-K Current report of material events | March 31, 2026 | View on SEC |
| 8-K Current report of material events | March 13, 2026 | View on SEC |
| 8-K Current report of material events | March 9, 2026 | View on SEC |
| 4 Insider stock transaction report | February 25, 2026 | View on SEC |
| 8-K Current report of material events | February 19, 2026 | View on SEC |
| 4 Insider stock transaction report | February 9, 2026 | View on SEC |
| 8-K Current report of material events | January 15, 2026 | View on SEC |
| 4 Insider stock transaction report | January 13, 2026 | View on SEC |
Annual Reports
10-K
March 31, 2026
- Advanced CDI-988 oral norovirus treatment into human challenge studies at Emory University.
- Maintains a robust intellectual property portfolio with over 50 patents extending into the 2040s.
Insider Trading
BUY
1 insiders
8 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.